Development of a Bioluminescent Cell-Based Assay to ... - Promega

More documents

Recommendations

Info

Bioassay development: Evaluating bioassay duration for response (fold induction) Evaluation of different induction hours for assay optimization using frozen, thawand-use Jurkat Effector cells with fresh-from-culture target cells (WIL2-S, CD20+) Bioluminescence Fold Induction Bioassay can be conducted with as few as 5-6hr induction using frozen, thaw-and-use Effector cells. Confidential and Proprietary. Not for Further Disclosure. 10
Bioassay development: Evaluating clone stability for engineered Jurkat effector cells Evaluation of stable effector cell line clone stability for assay optimization using frozen, thawand-use effector cells with fresh-from-culture WIL2-S target cells. Bioluminescence Fold Induction Frozen, thaw-and-use effector cell responsiveness was stable up to passage 25. (Current stability > passage 50) Confidential and Proprietary. Not for Further Disclosure. • E:T ratio = 7.5:1 • 6hr induction • Bio-Glo Assay Reagent 11
Page 1 and 2: Development of a Bioluminescent Cel
Page 3 and 4: Signaling pathways activated in eff
Page 5 and 6: Protocol 1. Reference or test antib
Page 7 and 8: FcgRIIIa antibody blocking of ADCC
Page 9: Bioassay development: Optimizing Ef
Page 13 and 14: Target cells can also be frozen, th
Page 15 and 16: ADCC Reporter Bioassay using frozen
Page 17 and 18: Precision, accuracy and linearity o
Page 19 and 20: ADCC Reporter Bioassay is stability
Page 21 and 22: Additional target cell option: Raji
Page 23 and 24: iological activity of therapeutic a
Page 25 and 26: Planned ADCC Reporter Bioassay kit
Page 27: For more information Confidential a

Development of a Bioluminescent Cell-Based Assay to ... - Promega

Create successful ePaper yourself

Delete template?

Save as template?